Efficacy and Safety of Dapagliflozin in Acute Heart Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.
Also called NCT04298229
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 240 participants
- Registry
-
NCT04298229
-
- Other papers using this trial's data
- Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure
- Interaction of Kidney Function and Dapagliflozin in Patients With Acute Heart Failure: A Pre-Specified Analysis of DICTATE-AHF
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04298229. Randomized; single masking; primary purpose treatment. Start 2020-04-01 (actual); primary completion 2023-05-17 (actual). Results posted on 2024-03-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Dapagliflozin in Acute Heart Failure
- Acronym
- DICTATE-AHF
- Condition
- Heart Failure
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dapagliflozin 10 MG
- Intervention (Other)
- Protocolized Diuretic Therapy
- Lead sponsor
- Vanderbilt University Medical Center
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct04298229- Content hash
15f413446f29fc6b9364dbf0783be46aa550ca1bf504d5c2340d5fbca57fe7ae